Board of Directors
Chairman of the Board
Mr. Lahat joined Nokia Siemens Networks in 2008 following acquisition of Atrica, a carrier-ethernet company that he had co-founded. At Nokia he served as Director of Product Management and Vice President of Business Development and Solutions. He headed Nokia’s global business ventures, establishing twelve internal startups and building the foundation for the company’s cloud business. He is also co-founder of Dyyno and has held executive and technical roles at 3Com/NiceCom and Nortel/Telrad.
He holds eleven granted patents in communication and IT domains.
Dr. Alan Levy
He then established and led multiple medical device companies, including Heartstream, that developed the first small, lightweight and easy-to-use automated external defibrillator.
Dr. Levy has also served as a Senior Advisor at Frazier Healthcare Ventures. He currently serves on the boards of multiple private and public healthcare companies.
Dr. Levy holds a BSc in Chemistry from City College of New York and a PhD and Honorary DSc from Purdue University.
CFO AND BOARD MEMBER
Previously Mr. Tabachnik has held a number of senior accounting positions in various distinguished firms in Israel and South Africa. Mr. Tabachnik is a Certified Public Accountant in Israel and holds a BA in Accounting and Economics from the Hebrew University of Jerusalem, Israel.
He has a proven track record of launching over 300 products in the pharmaceutical industry in Latin America and completing more than 20 licensing deals including biotech products and medical devices. He currently serves as a Board Member of Convexity Scientific, Via Surgical and Dog Parker. He previously served on the board of BMRC, a biotech research consortium in Chile.
Galit Zuckerman Stark
Founder, CEO and board member
Before founding Medasense she led a team of algorithm engineers at Applied Materials and worked at Nokia-Siemens and Nice Systems. She also served as a consultant for several start-up companies in the field of signal and image processing including BoneTone Communications which was successfully acquired by DSPG Inc in 2011.
Ms. Zuckerman Stark holds an MSc degree in Electrical Engineering (cum laude, Engineering Faculty Excellence Program) and a BSc in Computer Engineering (cum laude, Adi Lautman special program for outstanding students TAU) from Tel Aviv University, Israel.
Dr. Shmuel Cabilly
Today there are already twenty drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr. Cabilly was also a co-founder and a chief scientist of Ethrog Biotechnology where he invented major technologies in the field of chemistry.
Mr. Gavshon was a significant shareholder in, and served as an Executive Director of private and listed companies which developed icon brands. He has gained broad business experience in Australasia, USA and Asia and has been involved in a number of successful equity ventures where he has also taken Board and advisory roles.
Mr. Gavshon is widely respected for the extensive community service he has given and occupied leading positions in the Australian not-for-profit sector. He holds commerce and law degrees from the University of Witwatersrand, South Africa.
Anne E. Sissel
Prior to Veracyte, she worked in the Investment Banking Division of Goldman, Sachs & Co. in New York and San Francisco. Ms. Sissel has completed over $200B in financing and M&A transactions for clients in the healthcare and technology industries. Ms. Sissel was selected to Crain’s Chicago Top 50 in Tech List in 2015, Chicago Tribune Top Innovators 2016.
Ms. Sissel’s current Board and Observation roles include: Medasense, Opsonix, Inc., Sanifit S.L. and TVA Medical, Inc.B
He was responsible for the successful integration in Israel of the independent subsidiaries for leading American high-tech companies: K&S, KLA Instruments, and Applied Materials. Mr. Vilenski currently serves on the board of directors of several Israeli high-tech companies as well as on the boards of the Technion Institute and the Israeli National Nanotechnology Initiative.